About
Novartis AG focuses its business on three divisions: pharmaceuticals, eye care (Alcon), and generics (Sandoz). These three divisions are supported by the research organization, the Novartis Institutes for BioMedical Research, and a centralized services group, Novartis Business Services, to facilitate collaboration across the divisions and drive efficiency and productivity gains. In Israel, in addition to the marketing department, Novartis has a division engaged in medical research and development of new drugs and a wide range of clinical research activities. In 2009, Alcon, a subsidiary of Novartis, acquired Optonol, a company that develops devices for ophthalmologic applications and glaucoma surgery. Since its acquisition, Optonol operates as a subsidiary of the company. Novartis also operates in Israel a Cyber Security research center. Novartis is also present in Israel, through its innovation center BIOME.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Novartis become a public company and on which exchange?
- Novartis became public on the SIX exchange in April 1995.
- What was a significant acquisition made by Novartis's subsidiary Alcon in Israel?
- In 2009, Alcon, a subsidiary of Novartis, acquired Optonol, an Israeli company developing devices for ophthalmologic applications and glaucoma surgery. Optonol has since operated as a subsidiary of Novartis.
- What types of operations does Novartis conduct in Israel?
- In Israel, Novartis has a marketing department, a division for medical research and development of new drugs, clinical research activities, a Cyber Security research center, and an innovation center called BIOME.
- What was Novartis's investment in Ayala Pharmaceuticals in December 2018?
- In December 2018, Novartis invested $10 million in the anti-cancer company Ayala Pharmaceuticals and also signed a licensing deal with them for a blood cancer drug.
- Did Novartis participate in Gamida Cell's IPO?
- In October 2018, Novartis announced its intention to invest in Gamida Cell's $60 million Nasdaq IPO.
- What is the approximate number of employees Novartis has in Israel?
- Novartis employs between 51 and 200 people in Israel, with an exact count of 180 employees.
- What is Novartis's primary business focus?
- Novartis AG focuses its business on three divisions: pharmaceuticals, eye care (Alcon), and generics (Sandoz).
- What is the market capitalization of Novartis?
- As of January 1, 2026, Novartis has a market capitalization of $265,006,283,295.